Exhibit 99.1

                                        COMPANY CONTACT:
                                        Steve P. Loomis, Chief Financial Officer
                                        sloomis@cardiodynamics.com
                                        800-778-4825, Ext. 1015

                   CardioDynamics Board of Directors Proposes
                     Reverse Split 1:7 of Company's Shares

        Split Intended to Maintain Nasdaq Listing and Attract Additional
                 Investors as Company Enters Next Growth Phase

      SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq:
CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG)
technology, today announced that its Board of Directors has approved a
resolution proposing a reverse split of 1 for 7 shares of the Company's common
stock. The proposed reverse split is expected to become effective, subject to
shareholder approval, shortly after the Company's May 8, 2008, Annual
Shareholders Meeting.

      In the reverse split, each seven (7) shares of CardioDynamics common stock
issued and outstanding will be combined into one (1) share of common stock,
which initially should have the effect of proportionately increasing the stock
price. Following the reverse split, the total number of shares outstanding will
be reduced to approximately 7.2 million shares. Additionally, the reverse split
will affect all shares of CardioDynamics common stock proportionally, including
its Convertible Notes and outstanding stock options.

      Michael K. Perry, CardioDynamics Chief Executive Officer, stated,
"Recently, a number of our largest shareholders have expressed overwhelming
support to affect a reverse split to maintain our Nasdaq listing and attract a
greater level of interest among investors and analysts. We also believe the
reverse split comes at an excellent time and is complementary with the positive
turnaround occurring in our business. Not only do we think the capital
structure, post-reverse split, will be more attractive to potential investors,
but our recent four consecutive quarters of revenue growth, international sales
momentum, continued growth plan for 2008, and intense focus on achieving
positive operating cash flow by the fourth quarter of 2008, should all be
positive catalysts for new investors."

      In November, 2007, the Company transferred to the Nasdaq Capital Market
and has until April 14, 2008, to maintain a minimum bid price of $1.00 per share
for 10 or more consecutive days in order to meet the continued listing
requirements. The Company anticipates receiving a notice of noncompliance in
April, 2008, and if so, will request a hearing with Nasdaq to present its plan
to achieve compliance which will include the intention to seek prompt
shareholder approval of the reverse stock split.





      About CardioDynamics:

      CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and
leader of an important medical technology called BioZ(R) Impedance Cardiography
(ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG
products. The Company's BioZ(R) ICG Systems are being used by physicians around
the world to help battle the number one killer of men and women --
cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems,
and Mindray. For additional information, please refer to the company's Web site
at http://www.cdic.com.

      Forward-Looking (Safe Harbor) Statement:

      Except for the historical and factual information contained herein, this
press release contains forward-looking statements, such as potential Nasdaq
listing compliance, future growth and positive cash flow beliefs, the accuracy
of which is necessarily subject to uncertainties and risks including the
Company's sole dependence on the BioZ(R) product line, and various uncertainties
characteristic of early growth companies, as well as other risks detailed in the
Company's filings with the SEC, including its 2007 Form 10-K. The Company does
not undertake to update the disclosures contained in this press release.